|Bid||0.00 x 1100|
|Ask||62.65 x 800|
|Day's Range||36.24 - 38.53|
|52 Week Range||35.40 - 83.45|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Regenxbio (RGNX) delivered earnings and revenue surprises of -44.00% and -65.15%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
President and CEO of Regenxbio Inc (30-Year Financial, Insider Trades) Kenneth T. Mills (insider trades) sold 15,000 shares of RGNX on 07/19/2019 at an average price of $49.49 a share. Continue reading...
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
The delivery of the Novartis gene therapy for a lethal disease has a strong tie to Penn researchers.
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 89 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
A second baby reportedly died in a study of Novartis' gene therapy, Zolgensma — sending shares of biotech Regenxbio into free fall Monday. Regenxbio lost nearly 8% by the closing bell.
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. F...
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.